93,000 patients studied: what decades of data reveal about carcinoid cancer survival
NCT ID NCT07317713
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at nearly 94,000 people diagnosed with gastrointestinal carcinoid tumors between 2000 and 2022. Researchers used a large cancer database to calculate how many patients died from their tumor compared to the general population. The goal was to fill gaps in knowledge about long-term survival for these rare, slow-growing cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could help doctors better predict survival and tailor follow-up for people with gastrointestinal carcinoid tumors.
- What could go wrong
- This is an observational study using existing data, not a treatment trial. It cannot prove what causes better or worse outcomes, only highlight patterns.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo aims to stall rare gut tumors
- New CT technique may spot Hard-to-Find gut tumors
- New hope for rare tumors: tarlatamab trial opens
- Could a simple dose change make a tough cancer drug easier to take?
- Massive study reveals hidden cancer risk in rare gut tumor patients
- Big data reveals shifting patterns in rare cancer diagnosis